{"title":"一种检测献血者HIV-1/ 2抗体的新方法的特异性","authors":"C Saadé, T Wüst","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of the continuous development of anti-HIV-ELISA tests is the improvement of their specificity and sensitivity. With this study the precision and the specificity of the Cobas Core Anti-HIV-1/HIV-2 DAGS, a 3rd-generation anti-HIV assay, were evaluated.</p><p><strong>Materials and methods: </strong>1,557 frozen and 1,654 fresh sera from blood donors were tested with the Cobas Core Anti-HIV-1/HIV-2 DAGS (Roche Diagnostic Systems, Basel, Switzerland) and the Abbott Recombinant HIV-1/HIV-2 3rd Generation EIA (Abbott GmbH Diagnostika, Wiesbaden, Germany), which was used as a reference assay. Positive sera were tested with a Westernblot. 34 sera, previously not negative in the Abbott test, were retested with the two anti-HIV assays and with a Westernblot. The intra- and inter-assay precision was evaluated with the positive and negative controls of the test kits and with control sera.</p><p><strong>Results: </strong>The intra- and inter-assay precision of the Roche test was very good. The specificity of the Roche test is 99.91%. Out of 3,211 tested sera those of three blood donors were false positive in the Roche test and one sample false positive in the Abbott test.</p><p><strong>Conclusions: </strong>The precision and specificity of the new anti-HIV test fulfil the demands of transfusion medicine.</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 3","pages":"133-7"},"PeriodicalIF":0.0000,"publicationDate":"1996-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Specificity of a new test for detection of antibodies to HIV-1/-2 in blood donors].\",\"authors\":\"C Saadé, T Wüst\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The aim of the continuous development of anti-HIV-ELISA tests is the improvement of their specificity and sensitivity. With this study the precision and the specificity of the Cobas Core Anti-HIV-1/HIV-2 DAGS, a 3rd-generation anti-HIV assay, were evaluated.</p><p><strong>Materials and methods: </strong>1,557 frozen and 1,654 fresh sera from blood donors were tested with the Cobas Core Anti-HIV-1/HIV-2 DAGS (Roche Diagnostic Systems, Basel, Switzerland) and the Abbott Recombinant HIV-1/HIV-2 3rd Generation EIA (Abbott GmbH Diagnostika, Wiesbaden, Germany), which was used as a reference assay. Positive sera were tested with a Westernblot. 34 sera, previously not negative in the Abbott test, were retested with the two anti-HIV assays and with a Westernblot. The intra- and inter-assay precision was evaluated with the positive and negative controls of the test kits and with control sera.</p><p><strong>Results: </strong>The intra- and inter-assay precision of the Roche test was very good. The specificity of the Roche test is 99.91%. Out of 3,211 tested sera those of three blood donors were false positive in the Roche test and one sample false positive in the Abbott test.</p><p><strong>Conclusions: </strong>The precision and specificity of the new anti-HIV test fulfil the demands of transfusion medicine.</p>\",\"PeriodicalId\":13632,\"journal\":{\"name\":\"Infusionstherapie und Transfusionsmedizin\",\"volume\":\"23 3\",\"pages\":\"133-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1996-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infusionstherapie und Transfusionsmedizin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infusionstherapie und Transfusionsmedizin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Specificity of a new test for detection of antibodies to HIV-1/-2 in blood donors].
Background: The aim of the continuous development of anti-HIV-ELISA tests is the improvement of their specificity and sensitivity. With this study the precision and the specificity of the Cobas Core Anti-HIV-1/HIV-2 DAGS, a 3rd-generation anti-HIV assay, were evaluated.
Materials and methods: 1,557 frozen and 1,654 fresh sera from blood donors were tested with the Cobas Core Anti-HIV-1/HIV-2 DAGS (Roche Diagnostic Systems, Basel, Switzerland) and the Abbott Recombinant HIV-1/HIV-2 3rd Generation EIA (Abbott GmbH Diagnostika, Wiesbaden, Germany), which was used as a reference assay. Positive sera were tested with a Westernblot. 34 sera, previously not negative in the Abbott test, were retested with the two anti-HIV assays and with a Westernblot. The intra- and inter-assay precision was evaluated with the positive and negative controls of the test kits and with control sera.
Results: The intra- and inter-assay precision of the Roche test was very good. The specificity of the Roche test is 99.91%. Out of 3,211 tested sera those of three blood donors were false positive in the Roche test and one sample false positive in the Abbott test.
Conclusions: The precision and specificity of the new anti-HIV test fulfil the demands of transfusion medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
